Morgan Stanley analyst Michael Ulz has maintained their bullish stance on SLN stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz has given his Buy rating due to a combination of factors related to Silence Therapeutics’ promising clinical data and ongoing developments. The updated Phase 1 data from the SANRECO study demonstrated significant reductions in the need for phlebotomies among patients with polycythemia vera, particularly those with well-controlled hematocrit levels. This suggests that the treatment, divesiran, is effective in managing the condition with a favorable safety profile, as most adverse events were mild and did not lead to discontinuation.
Additionally, the Phase 2 portion of the study is progressing well, with over half of the targeted patient enrollment completed and on track for timely completion. This progress supports the potential of divesiran as a viable treatment option, with a topline readout expected in the fourth quarter of 2026. These developments indicate a positive outlook for Silence Therapeutics, justifying the Buy rating.
According to TipRanks, Ulz is an analyst with an average return of -1.6% and a 42.72% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Rhythm Pharmaceuticals.